These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21396961)

  • 21. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir.
    Shaw T; Mok SS; Locarnini SA
    Hepatology; 1996 Nov; 24(5):996-1002. PubMed ID: 8903366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.
    Ladner SK; Miller TJ; Otto MJ; King RW
    Antivir Chem Chemother; 1998 Jan; 9(1):65-72. PubMed ID: 9875378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
    Hacker HJ; Zhang W; Tokus M; Bock T; Schröder CH
    Ann N Y Acad Sci; 2004 Jun; 1022():271-81. PubMed ID: 15251972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.
    Tadokoro K; Suzuki F; Kobayashi M; Yamaguchi T; Nagano M; Egashira T; Kumada H
    J Virol Methods; 2011 Jan; 171(1):67-73. PubMed ID: 20950650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication.
    Kim HJ; Yoo HS; Kim JC; Park CS; Choi MS; Kim M; Choi H; Min JS; Kim YS; Yoon SW; Ahn JK
    J Ethnopharmacol; 2009 Jul; 124(2):189-96. PubMed ID: 19409970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro.
    Liu Y; Miller MD; Kitrinos KM
    Antiviral Res; 2017 Mar; 139():25-31. PubMed ID: 28017761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro phenotyping of recombinant hepatitis B virus containing the polymerase/reverse transcriptase gene from clinical isolates.
    Liu Y; Kitrinos KM
    Methods Mol Biol; 2013; 1030():163-81. PubMed ID: 23821268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of HBV replication by antiviral microRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches.
    Kumar M; Follenzi A; Garforth S; Gupta S
    Antivir Ther; 2012; 17(3):519-28. PubMed ID: 22300804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Establishment of a stable cell line replicating hepatitis B virus DNA carrying the reverse transcriptase region derived from a clinical isolate].
    Xiang MQ; Cai XF; Zhang WL; Huang AL; Hu JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):13-8. PubMed ID: 23469784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.
    Baldick CJ; Tenney DJ; Mazzucco CE; Eggers BJ; Rose RE; Pokornowski KA; Yu CF; Colonno RJ
    Hepatology; 2008 May; 47(5):1473-82. PubMed ID: 18435459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency.
    Lin X; Yuan ZH; Wu L; Ding JP; Wen YM
    J Virol; 2001 Dec; 75(23):11827-33. PubMed ID: 11689664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
    Zhang J; Wang Y; Peng Y; Qin C; Liu Y; Li J; Jiang J; Zhou Y; Chang J; Wang Q
    Braz J Infect Dis; 2018; 22(6):477-486. PubMed ID: 30586543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel HBV recombinants between genotypes B and C in 3'-terminal reverse transcriptase (RT) sequences are associated with enhanced viral DNA load, higher RT point mutation rates and place of birth among Chinese patients.
    Liu B; Yang JX; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2018 Jan; 57():26-35. PubMed ID: 29111272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates.
    Zhou Y; Zhang Y; Yang X; Zhao J; Zheng L; Sun C; Jiang J; Yang Q; Wang Q; Chang J
    Antivir Ther; 2012; 17(8):1593-9. PubMed ID: 22910281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
    Wang YP; Liu F; He HW; Han YX; Peng ZG; Li BW; You XF; Song DQ; Li ZR; Yu LY; Cen S; Hong B; Sun CH; Zhao LX; Kreiswirth B; Perlin D; Shao RG; Jiang JD
    Antimicrob Agents Chemother; 2010 May; 54(5):2070-7. PubMed ID: 20176893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.
    Yang H; Westland C; Xiong S; Delaney WE
    Antiviral Res; 2004 Jan; 61(1):27-36. PubMed ID: 14670591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.
    Nakajima S; Watashi K; Fukano K; Tsukuda S; Wakae K; Aizaki H; Muramatsu M; Wakita T; Toyoda T
    J Gastroenterol; 2020 Apr; 55(4):441-452. PubMed ID: 31768802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.